Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-68
Letter to the Editor
Chun, Felix K × de la Taille, Alexandre Van Poppel, Hendrik Marberger, Michael Stenzl, Arnulf Mulders, Peter F A Huland, Hartwig Abbou, Clement-Claude Stillebroer, Alexander B van Gils, Martijn P M Q Schalken, Jack A Fradet, Yves Marks, Leonard S Ellis, William Partin, Alan W Haese, Alexander #
European Urology vol:57 issue:1 pages:E2-E3
Our paper investigated prostate cancer gene 3 (PCA3) in the largest reported cohort to date of men at risk of prostate cancer (PCa) (n = 809) . All patients from two prospective, multicenter studies from Europe and North America, were subjected to ≥10 cores at either initial or repeat prostate biopsy. We clearly demonstrate that the urinary marker PCA3 represents a novel, informative PCa detection marker. Furthermore, we report the first internally validated PCA3-based nomograms that accurately identify individuals at risk of harboring PCa. Thus, if a PCA3 score is available in combination with established risk factors, these novel nomograms assist clinicians in deciding whether further prostatic evaluation is necessary.